Pharma Focus Asia

AstraZeneca Invests US$1.5 billion for New Manufacturing Facility in Singapore


AstraZeneca is set to invest US$1.5 billion to open a new manufacturing facility for antibody drug conjugates (ADCs) in Singapore.


This state-of-the-art greenfield facility will be the first to provide end-to-end ADC production, encompassing all stages of the manufacturing process at a commercial scale.

This significant investment highlights biopharmaceutical manufacturing capabilities and talent. It bolsters Singapore's ecosystem, facilitating the development and production of precision medicines, and generates significant employment and economic opportunities.

The multi-step process of manufacturing ADCs involves antibody production, synthesis of the chemotherapy drug and linker, conjugation of the drug-linker to the antibody, and filling the completed ADC substance.

The new facility will be designed to emit zero carbon from its first day of operations commencing design and construction by the end of 2024, with a target for operational readiness by 2029.


Name       AstraZeneca
Type         New Manufacturing Facility
Budget   US$1.5 billion
Year          2024


magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference